《大行報告》摩通上調創科(00669.HK)目標價至136元 予「增持」評級
摩根大通發表報告,重予創科(00669.HK)「增持」評級,按現金流折現率作估值,對其目標價由108港元上調至136港元。該行看好全球電動工具行業前景,並指公司在美國業務佈局良好。
該行相信憑藉創新能力及供應鏈管理能力,創科未來表現可優於同業,支持其進一步增長;該行看好創科良好執行力及強勁的產品,料創科估值可達明年預測市盈率34倍,較全球同業預測市盈率28倍有估值溢價。
摩通料創科於2020年至2022年每股經調整盈利預測分別為0.39美元、0.47美元及0.57美元。(wl/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.